{"title":"以叶酸为中心的发病机制概念和GBINC个性化多学科方法对儿童神经精神综合征的临床管理。审查","authors":"D. Maltsev","doi":"10.30978/unj2022-3-5","DOIUrl":null,"url":null,"abstract":"Solving the problem of children’s neuropsychiatric diseases is a priority task of modern medicine. The latest scientific achievements in the field of genetics, molecular biology and immunology, which demonstrate biochemical and immune‑dependent ways of formation of human neuropsychiatric disorders, shed light on the mechanisms of brain damage in children with ASD. These research give reason for optimism about overcoming this severe psychiatric pathology in the future thanks to the implementation of genetic, biochemical and immunodiagnostic approaches, as well as metabolic and immunotherapeutic interventions with neuroprotective effects. Currently, the folate‑centric concept of polygenic inheritance of predisposition to the development of neuropsychiatric syndromes in children with multisystem damage has been established. Biochemical and immune‑dependent (infectious, autoimmune, immunoinflammatory, and allergic) pathways of microbe‑induced autoimmune inflammatory encephalopathy with neuropsychiatric clinical manifestations are discussed in the context of the folate‑centric concept. Taking into account the new data, two personalized multidisciplinary approaches to the management of children with ASD and other neuropsychiatric syndromes are proposed. The first approach of J. J. Bradstreet et al. (2010) is based on the empirical analysis of a large group of laboratory biomarkers, the relevance of which has been demonstrated in clinical studies, and the targeted correction of abnormalities identified by biomarkers (so‑called biomarker‑guided interventions). In 2022, Frye R. developed a multidisciplinary personalized approach called BaS‑BiSTOR (collect Baseline data, search for Symptoms, measure Biomarkers, Select Treatment, Observe for Response), which systematizes and stratifies diagnostic and treatment interventions based on the assessment of biomarkers. In order to improve existing recommendations regarding specific subtypes of neuropsychiatric syndromes in children, this article proposes an improved personalized multidisciplinary approach to the clinical management of patients with autistic spectrum disorders and neuropsychiatric manifestations associated with genetic deficiency of the folate cycle, called GBINS (Genetic‑Biochemical‑Immunological‑Neurological‑Symptomatic evaluation). There are reasons to believe that the successful testing in clinical practice of evidence‑based personalized multidisciplinary diagnostic and treatment strategies will allow making a breakthrough in the clinical management of children with severe mental disorders in the near future, which will provide not only the possibility of recovery from a prognostically unfavorable and currently incurable neuropsychiatric disorder, but also and will contribute to stopping the large‑scale threatening epidemic of neuropsychiatric syndromes in the modern child population. \n ","PeriodicalId":296251,"journal":{"name":"Ukrainian Neurological Journal","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2022-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The folate-centric concept of pathogenesis and GBINC personalized multidisciplinary approach to the clinical management of children with neuropsychiatric syndromes. Review\",\"authors\":\"D. Maltsev\",\"doi\":\"10.30978/unj2022-3-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Solving the problem of children’s neuropsychiatric diseases is a priority task of modern medicine. The latest scientific achievements in the field of genetics, molecular biology and immunology, which demonstrate biochemical and immune‑dependent ways of formation of human neuropsychiatric disorders, shed light on the mechanisms of brain damage in children with ASD. These research give reason for optimism about overcoming this severe psychiatric pathology in the future thanks to the implementation of genetic, biochemical and immunodiagnostic approaches, as well as metabolic and immunotherapeutic interventions with neuroprotective effects. Currently, the folate‑centric concept of polygenic inheritance of predisposition to the development of neuropsychiatric syndromes in children with multisystem damage has been established. Biochemical and immune‑dependent (infectious, autoimmune, immunoinflammatory, and allergic) pathways of microbe‑induced autoimmune inflammatory encephalopathy with neuropsychiatric clinical manifestations are discussed in the context of the folate‑centric concept. Taking into account the new data, two personalized multidisciplinary approaches to the management of children with ASD and other neuropsychiatric syndromes are proposed. The first approach of J. J. Bradstreet et al. (2010) is based on the empirical analysis of a large group of laboratory biomarkers, the relevance of which has been demonstrated in clinical studies, and the targeted correction of abnormalities identified by biomarkers (so‑called biomarker‑guided interventions). In 2022, Frye R. developed a multidisciplinary personalized approach called BaS‑BiSTOR (collect Baseline data, search for Symptoms, measure Biomarkers, Select Treatment, Observe for Response), which systematizes and stratifies diagnostic and treatment interventions based on the assessment of biomarkers. In order to improve existing recommendations regarding specific subtypes of neuropsychiatric syndromes in children, this article proposes an improved personalized multidisciplinary approach to the clinical management of patients with autistic spectrum disorders and neuropsychiatric manifestations associated with genetic deficiency of the folate cycle, called GBINS (Genetic‑Biochemical‑Immunological‑Neurological‑Symptomatic evaluation). There are reasons to believe that the successful testing in clinical practice of evidence‑based personalized multidisciplinary diagnostic and treatment strategies will allow making a breakthrough in the clinical management of children with severe mental disorders in the near future, which will provide not only the possibility of recovery from a prognostically unfavorable and currently incurable neuropsychiatric disorder, but also and will contribute to stopping the large‑scale threatening epidemic of neuropsychiatric syndromes in the modern child population. \\n \",\"PeriodicalId\":296251,\"journal\":{\"name\":\"Ukrainian Neurological Journal\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-12-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ukrainian Neurological Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30978/unj2022-3-5\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ukrainian Neurological Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30978/unj2022-3-5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
解决儿童神经精神疾病问题是现代医学的首要任务。遗传学、分子生物学和免疫学领域的最新科学成果,揭示了人类神经精神疾病的生化和免疫依赖形成方式,为ASD儿童脑损伤的机制提供了线索。这些研究让我们有理由乐观地认为,由于遗传、生化和免疫诊断方法的实施,以及具有神经保护作用的代谢和免疫治疗干预,未来将克服这种严重的精神病理学。目前,以叶酸为中心的多基因遗传易感性的概念已经在多系统损伤儿童中建立起来。在以叶酸为中心的概念背景下,讨论了微生物诱导的具有神经精神临床表现的自身免疫性炎症性脑病的生化和免疫依赖(感染、自身免疫、免疫炎症和过敏)途径。考虑到这些新的数据,我们提出了两种个性化的多学科方法来治疗自闭症儿童和其他神经精神综合征。J. J. Bradstreet等人(2010)的第一种方法是基于对大量实验室生物标志物的实证分析,其相关性已在临床研究中得到证明,并有针对性地纠正生物标志物识别的异常(所谓的生物标志物引导干预)。2022年,Frye R.开发了一种名为BaS - BiSTOR(收集基线数据,搜索症状,测量生物标志物,选择治疗,观察反应)的多学科个性化方法,该方法基于生物标志物的评估将诊断和治疗干预措施系统化和分层。为了改进现有关于儿童特定亚型神经精神综合征的建议,本文提出了一种改进的个性化多学科方法,用于自闭症谱系障碍患者的临床管理和与叶酸周期遗传缺乏相关的神经精神表现,称为GBINS(遗传-生化-免疫-神经-症状评估)。有理由相信,基于证据的个性化多学科诊断和治疗策略在临床实践中的成功测试,将在不久的将来使患有严重精神障碍的儿童的临床管理取得突破,这不仅将提供从预后不利且目前无法治愈的神经精神障碍中恢复的可能性,同时也将有助于阻止现代儿童中神经精神综合征的大规模威胁流行。
The folate-centric concept of pathogenesis and GBINC personalized multidisciplinary approach to the clinical management of children with neuropsychiatric syndromes. Review
Solving the problem of children’s neuropsychiatric diseases is a priority task of modern medicine. The latest scientific achievements in the field of genetics, molecular biology and immunology, which demonstrate biochemical and immune‑dependent ways of formation of human neuropsychiatric disorders, shed light on the mechanisms of brain damage in children with ASD. These research give reason for optimism about overcoming this severe psychiatric pathology in the future thanks to the implementation of genetic, biochemical and immunodiagnostic approaches, as well as metabolic and immunotherapeutic interventions with neuroprotective effects. Currently, the folate‑centric concept of polygenic inheritance of predisposition to the development of neuropsychiatric syndromes in children with multisystem damage has been established. Biochemical and immune‑dependent (infectious, autoimmune, immunoinflammatory, and allergic) pathways of microbe‑induced autoimmune inflammatory encephalopathy with neuropsychiatric clinical manifestations are discussed in the context of the folate‑centric concept. Taking into account the new data, two personalized multidisciplinary approaches to the management of children with ASD and other neuropsychiatric syndromes are proposed. The first approach of J. J. Bradstreet et al. (2010) is based on the empirical analysis of a large group of laboratory biomarkers, the relevance of which has been demonstrated in clinical studies, and the targeted correction of abnormalities identified by biomarkers (so‑called biomarker‑guided interventions). In 2022, Frye R. developed a multidisciplinary personalized approach called BaS‑BiSTOR (collect Baseline data, search for Symptoms, measure Biomarkers, Select Treatment, Observe for Response), which systematizes and stratifies diagnostic and treatment interventions based on the assessment of biomarkers. In order to improve existing recommendations regarding specific subtypes of neuropsychiatric syndromes in children, this article proposes an improved personalized multidisciplinary approach to the clinical management of patients with autistic spectrum disorders and neuropsychiatric manifestations associated with genetic deficiency of the folate cycle, called GBINS (Genetic‑Biochemical‑Immunological‑Neurological‑Symptomatic evaluation). There are reasons to believe that the successful testing in clinical practice of evidence‑based personalized multidisciplinary diagnostic and treatment strategies will allow making a breakthrough in the clinical management of children with severe mental disorders in the near future, which will provide not only the possibility of recovery from a prognostically unfavorable and currently incurable neuropsychiatric disorder, but also and will contribute to stopping the large‑scale threatening epidemic of neuropsychiatric syndromes in the modern child population.